| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
118,506,000 |
| Market
Cap: |
462.17(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.65 - $8.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 7.7 |
| Insider 3/6 Months : 8.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fate Therapeutics is a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for patients with cancer. Co. is developing cell therapy product candidate. Co.'s off-the-shelf, induced pluripotent stem cells (iPSC) derived cellular immunotherapy pipeline include: FT516, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a high-affinity, non-cleavable CD16 Fc receptor; and FT596, which is an off-the-shelf chimeric antigen receptor NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
44,630 |
44,630 |
471,648 |
| Total Buy Value |
$0 |
$166,024 |
$166,024 |
$2,724,191 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
6 |
| Total Shares Sold |
2,447 |
78,990 |
96,836 |
590,364 |
| Total Sell Value |
$19,013 |
$301,730 |
$380,390 |
$5,527,958 |
| Total People Sold |
1 |
4 |
6 |
14 |
| Total Sell Transactions |
1 |
9 |
14 |
36 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Agarwal Shefali |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
8,650 |
10,490 |
|
- |
|
| Green Jeremy |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
I/I |
8,650 |
12,968,553 |
|
- |
|
| Jooss Karin |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
8,650 |
9,848 |
|
- |
|
| Xu Yuan |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
8,650 |
13,394 |
|
- |
|
| Rastetter William H |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
8,650 |
11,331 |
|
- |
|
| Mendlein John |
Director |
– • – |
2022-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
8,650 |
166,741 |
|
- |
|
| Agarwal Shefali |
Director |
– • – |
2022-06-07 |
4 |
S |
$21.89 |
$18,409 |
D/D |
(841) |
1,840 |
|
13% |
|
| Agarwal Shefali |
Director |
– • – |
2022-06-03 |
4/A |
S |
$0.00 |
$0 |
D/D |
(0) |
2,681 |
|
- |
|
| Mendlein John |
Director |
– • – |
2022-06-03 |
4 |
S |
$22.79 |
$31,086 |
D/D |
(1,364) |
158,091 |
|
9% |
|
| Hershberg Robert |
Director |
– • – |
2022-06-03 |
4 |
S |
$22.75 |
$15,288 |
D/D |
(672) |
2,009 |
|
9% |
|
| Jooss Karin |
Director |
– • – |
2022-06-03 |
4 |
S |
$22.82 |
$33,842 |
D/D |
(1,483) |
1,198 |
|
9% |
|
| Agarwal Shefali |
Director |
– • – |
2022-06-03 |
4 |
S |
$22.80 |
$18,400 |
D/D |
(807) |
1,874 |
|
9% |
|
| Coughlin Timothy P |
Director |
– • – |
2022-06-03 |
4 |
S |
$22.81 |
$32,824 |
D/D |
(1,439) |
57,632 |
|
9% |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2022-06-01 |
4 |
AS |
$22.96 |
$574,000 |
D/D |
(25,000) |
189,151 |
|
-8% |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2022-06-01 |
4 |
OE |
$6.55 |
$163,750 |
D/D |
25,000 |
214,151 |
|
- |
|
| Wolchko J Scott |
President and CEO |
• • – |
2022-04-22 |
4 |
AS |
$34.54 |
$345,911 |
D/D |
(10,000) |
431,546 |
|
-22% |
|
| Wolchko J Scott |
President and CEO |
• • – |
2022-04-22 |
4 |
OE |
$2.70 |
$27,000 |
D/D |
10,000 |
441,546 |
|
- |
|
| Wolchko J Scott |
President and CEO |
• • – |
2022-04-21 |
4 |
AS |
$34.57 |
$1,049,881 |
D/D |
(30,000) |
431,546 |
|
-24% |
|
| Wolchko J Scott |
President and CEO |
• • – |
2022-04-21 |
4 |
OE |
$2.70 |
$81,000 |
D/D |
30,000 |
461,546 |
|
- |
|
| Chu Yu-Waye |
Chief Medical Officer |
• – – |
2022-04-19 |
4 |
S |
$35.37 |
$143,673 |
D/D |
(4,062) |
151,033 |
|
27% |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2022-04-01 |
4 |
AS |
$38.85 |
$971,250 |
D/D |
(25,000) |
189,151 |
|
-21% |
|
| Tahl Cindy |
General Counsel and Secretary |
• – – |
2022-04-01 |
4 |
OE |
$4.84 |
$130,520 |
D/D |
25,000 |
214,151 |
|
- |
|
| Valamehr Bahram |
Chief R&D Officer |
• – – |
2022-03-14 |
4 |
AS |
$30.36 |
$776,733 |
D/D |
(25,000) |
179,834 |
|
5% |
|
| Valamehr Bahram |
Chief R&D Officer |
• – – |
2022-03-14 |
4 |
OE |
$2.73 |
$68,250 |
D/D |
25,000 |
204,834 |
|
- |
|
| Mendlein John |
Director |
– • – |
2022-03-10 |
4 |
AS |
$34.73 |
$1,105,200 |
D/D |
(31,562) |
159,455 |
|
-8% |
|
297 Records found
|
|
Page 3 of 12 |
|
|
0.20 (5.41%) 
